Symptoms and quality of life in adults living with metastatic colorectal cancer
Official title: Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer
Funded at Georgetown University · NIH-11162244 · Data updated 2026-11-12
Researchers will follow adults with metastatic colorectal cancer over time to learn what symptoms and quality-of-life issues they experience during treatment and survivorship.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $707,923 |
| NIH project number | 5R01CA281752-03 |
| Project ID | NIH-11162244 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 18 or older diagnosed with metastatic colorectal cancer who can complete repeated questionnaires and are willing to be followed over time, especially those living in New Jersey or Greater California, are ideal candidates.
✕Less likely to help
People without metastatic colorectal cancer, those with only early-stage disease, or anyone unwilling or unable to complete repeated surveys are unlikely to receive direct benefit from participating.
What this research studies
If you join, researchers will recruit adults (18+) diagnosed with metastatic colorectal cancer from population-based cancer registries in New Jersey and Greater California to include a diverse, real-world group. You will be asked to complete regular surveys about treatment side effects and your health-related quality of life over several years. Because the study uses population registries rather than clinical trials, it aims to include people often left out of research and to track changes over time. The information will be used to identify unmet supportive care needs and guide future services and treatments for people living with metastatic colorectal cancer.
Why it matters
Potential benefit: If successful, this work could help clinicians and health systems target supportive care and symptom management to better meet the needs of people living with metastatic colorectal cancer.
How similar studies have gone: Most prior work has come from clinical trials of selected patients, so this population-based longitudinal approach is relatively novel and aims to capture more representative survivorship experiences.
Where this research is happening
-
Georgetown University
Washington, United States Active
Researchers
- Principal investigator: Potosky, Arnold L — Georgetown University
- Study coordinator: Potosky, Arnold L
Related research
Other NIH-funded projects on the same topics.
-
Population-based view of patient-reported outcomes in adults with metastatic colorectal cancer
This grant funds a long-term study to understand experiences and quality of life for adults living with metastatic colorectal cancer.
-
Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer
A new nanoscale therapy called CF10 is being developed to deliver a chemotherapy drug more directly to metastatic colorectal cancer, aiming for better tumor targeting and fewer side effects.
-
How metastatic colorectal cancer weakens muscles and bones
This research looks at how metastatic colorectal cancer and a hormone called FGF21 cause muscle and bone wasting in people with advanced colorectal cancer.
-
Nanoscale polymers delivering patient-specific cancer vaccines for metastatic colorectal cancer
A new therapy uses tiny, designer particles to carry patient-specific cancer antigens to tumors in people with advanced colorectal cancer.
-
Targeted nanoparticles combining chemotherapy and immune stimulation for advanced colon cancer
Targeted nanoparticles that deliver a two-drug chemotherapy combo plus immune-activating components are being developed to help people with metastatic colorectal (colon) cancer that usually does not respond to current immunotherapy.
-
miR-15a microRNA therapy for advanced metastatic colorectal cancer
A new treatment using a small RNA called miR-15a is being developed to help people, including Veterans, with advanced metastatic colorectal cancer that is resistant to standard chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.